Rates of hepatitis C virus (HCV) treatment in a commercially insured population doubled after availability of new direct-acting antivirals. Member out-of-pocket spending was kept low while the health plan bore 99% of spending on HCV medications.
Patients endure heavy medication complexity following hospital discharge for acute coronary syndrome.
In this analysis of patients with newly diagnosed hepatitis C, linkage to care was largely successful in the 1945-1965 birth cohort, but treatment initiation remained low. Check out our website’s new table/figure pop-up feature! Click on the name of a table or figure in the text to see it in your browser.
The role of federally qualified health centers is evaluated in serving uninsured patients and providing need-based, reduced-cost prescription medications in the post–Affordable Care Act landscape.
New hepatitis C medications have been quickly adopted into practice and increased treatment rate. The median out-of-pocket costs of new medications were relatively low.
Expanding primary care teams with trained and supported paraprofessionals enables systematic delivery of widely recommended, evidence-based, cost-saving alcohol, drug, and depression screening and intervention services.
From 2005 to 2009, improved clinical practice systems were associated with cost reductions only for medically complex patients.
This commentary reflects how high-performing healthcare organizations use health information technology to advance patient safety.
The annual price of monoclonal antibody therapies used in oncology and hematology is about $100,000 higher than those used in other disease states.
When a clinical staging algorithm for treatment-resistant depression was applied to administrative claims data, higher scores predicted higher future medical costs.
Care management patients experienced slightly greater improvements in CVD risk factor control than a set of matched controls. Both populations showed significant improvement over time.
Management of hepatitis C screening results can be optimized to ensure that patients receive high-quality care, reducing morbidity and costs related to the virus.
Through a multi-site, multidisciplinary approach, AYA@USC addresses the unique needs of young adult cancer patients, improving outcomes and bridging the care gap in this population.
Primary care teams reduced their prescribing of potentially inappropriate medications to older veterans after participation in the Veterans Affairs (VA) Geriatric Scholars Program.
This case study from the National Viral Hepatitis Roundtable and Project Inform describes the cost-sharing mechanisms that create significant barriers to accessing new hepatitis C treatments, which require a strong advocate response to improve patient access.